Twenty cases of mountain frostbites of various degrees are presented, showing that buflomedil hydrochloride allows an improvement of the usual treatment of frostbites. Two protocols were used: 1) in 8 patients, after the usual treatment (bath at 38 degrees C, dextran perfusion, heparintherapy, antibiotherapy), buflomedil hydrochlorhydrate was administered by perfusion of 8 vials/day, during 10 days; 2) in 12 patients, buflomedil was injected directly by intravenous route on their arrival in the Emergency room. When the injection is given early, a potentiation of the effects of the warm bath is observed, and in two cases, this therapy has perhaps allowed to avoid the amputation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Controlled simultaneous iontophoresis of buflomedil hydrochloride and dexamethasone sodium phosphate to the mucosa for oral submucous fibrosis.
Int J Pharm
September 2021
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland. Electronic address:
A novel concentric experimental set-up was used to investigate short-duration topical co-iontophoresis of cationic buflomedil hydrochloride (BUF) and anionic dexamethasone phosphate (DEX-P) to the oral mucosa. A constant current of 3.0 mA (0.
View Article and Find Full Text PDFDrug treatments in patients with cardiac diseases and epilepsy.
Acta Neurol Scand
July 2020
Science of Health Department, School of Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Objective: Comorbidity between epilepsy and heart diseases is frequent.
Methods: All drugs classified within the group of drugs for cardiovascular system according to the Anatomical Therapeutic Chemical (ATC) classification system were reviewed for their effects on seizures or epilepsy.
Results: Several agents showed antiseizure properties in animal models of seizures and/or in patients with epilepsy and only few were proconvulsant.
Pentoxifylline for intermittent claudication.
Cochrane Database Syst Rev
September 2015
Wessex Cardiothoracic Centre, University Hospital Southampton, Tremona Road, Southampton, UK, SO16 6YD.
Background: Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating individuals with PAD, but results of these studies are variable.
View Article and Find Full Text PDFBuflomedil for intermittent claudication.
Cochrane Database Syst Rev
March 2013
Heart Center, Ghent University Hospital, Ghent, Belgium.
Background: Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined.
View Article and Find Full Text PDF[Long-term functional outcomes of digital ischemia under tourniquet: observations in three cases].
Chir Main
December 2012
Service de chirurgie osseuse, centre hospitalier universitaire d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
Digital tourniquet is a quick, simple and reliable method to ensure a bloodless operative field distal to the MP joint. However, a forgotten tourniquet is an exceptional but serious complication related to digital ischemia. Few cases were reported in literature without a long-term outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!